Estuary Biotherapeutics reported raising $40.7 Million in an initial SEC Form D filing, from an offering of $104 Million
Amount Raised
$40.7 Million
Round Type
Series A
Menlo ParkBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
Estuary Biotherapeutics, which focuses on genetic medicines for serious kidney diseases, announced its launch with $103 million in total committed financing. The Series A funding of $93 million was led by RA Capital Management. Other investors included Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, and the National Kidney Foundation Innovation Fund. The funding will support the development of targeted gene therapies for kidney disease.
Quick answer
Estuary Biotherapeutics raised $40.7 Million in a Series A round, dated October 16, 2026. Investors: UPMC Enterprises, National Kidney Foundation Innovation Fund, Pivotal bioVenture Partners, Deep Track Capital, Biogen New Ventures and RA Capital Management. Estuary Biotherapeutics is based in Menlo Park, California, United States.
- How much did Estuary Biotherapeutics raise?
- Estuary Biotherapeutics raised $40.7 Million in a Series A round on October 16, 2026.
- Who invested in Estuary Biotherapeutics?
- UPMC Enterprises, National Kidney Foundation Innovation Fund, Pivotal bioVenture Partners, Deep Track Capital, Biogen New Ventures and RA Capital Management are named as investors in this round.
- What does Estuary Biotherapeutics do?
- Estuary Biotherapeutics, Inc. is a biotechnology company focused on developing genetic medicines for patients with serious kidney diseases.
- Where is Estuary Biotherapeutics based and how big is it?
- Estuary Biotherapeutics is based in Menlo Park, California, United States. Fundz records about 11 employees.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Estuary Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- VolitionRx raised $2.4M (Convertible Note) on October 27, 2026.
- seragy holding GmbH raised $13M on October 14, 2026.
- Aptadir Therapeutics raised $45M (Seed) on September 29, 2026.
- Typewriter Therapeutics raised $56M (Series A) on September 2, 2026.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
Who to call at Estuary Biotherapeutics, and when
A new round usually means Estuary Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Estuary Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Estuary Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Estuary Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Estuary Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansEstuary Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.